Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APENNASDAQ:ATECNASDAQ:LMATNASDAQ:NVCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPENApollo Endosurgery$9.94$3.49▼$10.30$579.72M2.311.43 million shs1.66 million shsATECAlphatec$11.35+3.8%$11.86$4.88▼$13.14$1.66B1.052.06 million shs932,965 shsLMATLeMaitre Vascular$84.32+1.6%$83.01$71.42▼$109.58$1.91B0.82169,551 shs63,021 shsNVCRNovoCure$17.26+2.2%$17.67$14.17▼$34.13$1.92B0.721.13 million shs531,541 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPENApollo Endosurgery0.00%0.00%0.00%0.00%0.00%ATECAlphatec-0.50%-1.53%-14.14%+15.91%+6.22%LMATLeMaitre Vascular-1.70%-0.08%-1.37%+6.53%-0.23%NVCRNovoCure-4.60%-5.11%-0.65%+9.89%+0.66%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPENApollo EndosurgeryN/AN/AN/AN/AN/AN/AN/AN/AATECAlphatec4.3375 of 5 stars3.41.00.03.33.54.20.6LMATLeMaitre Vascular2.4355 of 5 stars2.21.03.30.00.02.51.3NVCRNovoCure3.7133 of 5 stars3.41.00.04.52.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPENApollo Endosurgery 0.00N/AN/AN/AATECAlphatec 2.89Moderate Buy$17.8957.61% UpsideLMATLeMaitre Vascular 2.33Hold$97.8316.03% UpsideNVCRNovoCure 2.71Moderate Buy$32.4387.88% UpsideCurrent Analyst Ratings BreakdownLatest APEN, NVCR, LMAT, and ATEC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025NVCRNovoCureLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.006/27/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$34.006/16/2025ATECAlphatecLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$18.005/2/2025ATECAlphatecPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$13.00 ➝ $15.005/2/2025ATECAlphatecNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/23/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.004/16/2025NVCRNovoCureWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $27.004/14/2025ATECAlphatecHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/10/2025NVCRNovoCureJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $28.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPENApollo Endosurgery$76.86M0.00N/AN/A$0.69 per share0.00ATECAlphatec$642.27M2.58N/AN/A($0.10) per share-113.50LMATLeMaitre Vascular$226.26M8.42$2.39 per share35.33$15.00 per share5.62NVCRNovoCure$605.22M3.18N/AN/A$3.33 per share5.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPENApollo Endosurgery-$39.84M-$1.02N/AN/AN/A-51.84%-89.48%-33.76%N/AATECAlphatec-$162.12M-$1.15N/AN/AN/A-25.77%-1,657.19%-21.53%7/30/2025 (Estimated)LMATLeMaitre Vascular$44.04M$1.9842.5938.862.2319.96%13.53%9.78%7/30/2025 (Estimated)NVCRNovoCure-$168.63M-$1.51N/AN/AN/A-26.41%-45.46%-13.34%7/24/2025 (Estimated)Latest APEN, NVCR, LMAT, and ATEC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025ATECAlphatec-$0.06N/AN/AN/A$178.85 millionN/A7/24/2025Q2 2025NVCRNovoCure-$0.40N/AN/AN/A$153.87 millionN/A5/1/2025Q1 2025ATECAlphatec-$0.12-$0.35-$0.23-$0.35$167.57 million$169.18 million5/1/2025Q1 2025LMATLeMaitre Vascular$0.50$0.48-$0.02$0.48$57.61 million$59.87 million4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPENApollo EndosurgeryN/AN/AN/AN/AN/AATECAlphatecN/AN/AN/AN/AN/ALMATLeMaitre Vascular$0.800.95%N/A40.40%14 YearsNVCRNovoCureN/AN/AN/AN/AN/ALatest APEN, NVCR, LMAT, and ATEC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2025LMATLeMaitre Vascularquarterly$0.201%5/15/20255/15/20255/29/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPENApollo Endosurgery1.042.351.89ATECAlphatecN/A2.751.67LMATLeMaitre Vascular0.4816.4913.83NVCRNovoCure0.271.471.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPENApollo Endosurgery76.01%ATECAlphatec66.35%LMATLeMaitre Vascular84.64%NVCRNovoCure84.61%Insider OwnershipCompanyInsider OwnershipAPENApollo Endosurgery17.30%ATECAlphatec20.90%LMATLeMaitre Vascular9.50%NVCRNovoCure5.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPENApollo Endosurgery20257.97 million47.94 millionNot OptionableATECAlphatec700146.17 million112.85 millionOptionableLMATLeMaitre Vascular49022.59 million20.45 millionOptionableNVCRNovoCure1,488111.49 million105.33 millionOptionableAPEN, NVCR, LMAT, and ATEC HeadlinesRecent News About These CompaniesNovoCure (NASDAQ:NVCR) Coverage Initiated at LADENBURG THALM/SH SHJuly 8 at 8:40 AM | marketbeat.comSummit Trail Advisors LLC Acquires 40,570 Shares of NovoCure Limited (NASDAQ:NVCR)July 2, 2025 | marketbeat.comBrokerages Set NovoCure Limited (NASDAQ:NVCR) PT at $32.83July 2, 2025 | americanbankingnews.comStrong week for NovoCure (NASDAQ:NVCR) shareholders doesn't alleviate pain of three-year lossJune 30, 2025 | finance.yahoo.comNovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?June 30, 2025 | zacks.comNovoCure Limited (NASDAQ:NVCR) Shares Sold by Taylor Frigon Capital Management LLCJune 30, 2025 | marketbeat.comNovocure to Report Second Quarter 2025 Financial ResultsJune 30, 2025 | businesswire.comNovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Moderate Buy" by AnalystsJune 29, 2025 | marketbeat.comPiper Sandler Reiterates Overweight Rating for NovoCure (NASDAQ:NVCR)June 28, 2025 | americanbankingnews.comDemystifying NovoCure: Insights From 4 Analyst ReviewsJune 27, 2025 | benzinga.comNovoCure's (NVCR) "Overweight" Rating Reiterated at Piper SandlerJune 27, 2025 | marketbeat.comSG Americas Securities LLC Invests $527,000 in NovoCure Limited (NASDAQ:NVCR)June 23, 2025 | marketbeat.comNovoCure (NASDAQ:NVCR) Shares Down 3.4% - What's Next?June 18, 2025 | marketbeat.comWhat Makes NovoCure (NVCR) a New Buy StockJune 18, 2025 | zacks.comGAMMA Investing LLC Purchases 47,152 Shares of NovoCure Limited (NASDAQ:NVCR)June 17, 2025 | marketbeat.comSimon Quick Advisors LLC Takes Position in NovoCure Limited (NASDAQ:NVCR)June 16, 2025 | marketbeat.comNovoCure (NASDAQ:NVCR) Trading Up 6.5% - Here's WhyJune 10, 2025 | marketbeat.comNVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 TrialJune 6, 2025 | zacks.comResults From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual MeetingJune 2, 2025 | businesswire.comNovocure data support pancreatic cancer approval, says Wells FargoJune 2, 2025 | msn.comNovocure study shows improved pancreatic cancer survivalJune 2, 2025 | massdevice.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPEN, NVCR, LMAT, and ATEC Company DescriptionsApollo Endosurgery NASDAQ:APENApollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.Alphatec NASDAQ:ATEC$11.35 +0.42 (+3.84%) As of 02:57 PM EasternAlphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.LeMaitre Vascular NASDAQ:LMAT$84.32 +1.34 (+1.61%) As of 02:56 PM EasternLeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.NovoCure NASDAQ:NVCR$17.26 +0.37 (+2.19%) As of 02:57 PM EasternNovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
